Search
Iproniazid
go.drugbank.com/drugs/DB04818ApprovedWithdrawnWithdrawn from the Canadian market in July 1964 due to interactions with food products containing tyrosine.
Methylthioinosine
go.drugbank.com/drugs/DB02896ExperimentalAn analog of inosine with a methylthio group replacing the hydroxyl group in the 6-position.
MCMV5322A
go.drugbank.com/drugs/DB17763InvestigationalMCMV5322A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV3068A] to form RG7667.[A259362]
MCMV3068A
go.drugbank.com/drugs/DB17764InvestigationalMCMV3068A is an anticytomegalovirus monoclonal IgG1 antibody used in combination with [MCMV5322A] to form RG7667.[A259362]
GSK-945237
go.drugbank.com/drugs/DB15345Investigationaland Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc.). … GSK-945237 is under investigation in clinical trial NCT01039610 (A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose
Aluminum zirconium trichlorohydrex gly
go.drugbank.com/drugs/DB11116ApprovedWithdrawnThe compound forms a colloidal plug in sweat pores, preventing sweat from leaving the body. … Aluminum zirconium trichlorohydrex gly is a common active ingredient in deodorant and antiperspirant products for the over-the-counter use.
DLO6002
go.drugbank.com/drugs/DB05179ExperimentalDLO6002 is developed by Summit Corporation and is in phase I of clinical trials for the treatment of Parkinson's disease.
LY-2599506
go.drugbank.com/drugs/DB05970InvestigationalLY2599506 was under investigation in clinical trials NCT01024244 and NCT01029795 for the treatment of patients with type 2 diabetes.
Synonyms: (R)-2-(4-(CYCLOPROPYLSULFONYL)PHENYL)-N-(PYRAZIN-2-YL)-3-(TETRAHYDRO-2H-PYRAN-4-YL)PROPANAMIDEEtesevimab
go.drugbank.com/drugs/DB15897Investigational[L16651,L16661] Under the EUA granted in February 2021, etesevimab is used in combination with [bamlanivimab] to treat mild to moderate COVID-19 in adults and pediatric patients who are at high risk for … [L40174] The EUA currently allows bamlanivimab and etesevimab for post-exposure prophylaxis of COVID-19 in adults and children.[L40179]